ReviewVirology2020
The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.
Review in Virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05162482 (Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan), which is not on this map. Cited by 128 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial
Who cites it
128 citing papers in PubMed, 1 synthesis or guideline pooled it, 279 citations in OpenAlex.
- Epigenetic changes in patients with post-acute COVID-19 symptoms (PACS) and long-COVID: A systematic review.Expert reviews in molecular medicine · 2024Pooled it
- Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.Clinics (Sao Paulo, Brazil) · 2023Trial
- Development and validation of a prediction model for adverse outcomes in viral pneumonia using CT-based quantitative body composition analysis.Journal of thoracic disease · 2026Article
- Transplacental Antibody Transfer: Mechanisms, Pregnancy-Related Disruptions, and Emerging Experimental Models.Antibodies (Basel, Switzerland) · 2026Review
- Long-term motor stability but increasing non-motor burden in multifocal motor neuropathy: a 6-year real-world follow-up study during the COVID-19 era.Frontiers in human neuroscience · 2026Article
- A descriptive multilevel analysis associating COVID-19 with polymyositis: from genetic markers and candidate mediators to clinical hematological profiles.Frontiers in medicine · 2026Article
- Explainable machine learning-based mortality risk stratification for older adults with COVID-19: pinpointing core immunological biomarkers and revealing dose-threshold effects.Frontiers in immunology · 2026Article
- Clinical Predictors of Weaning Failure and Mortality in Individuals With COVID-19 Undergoing Invasive Mechanical Ventilation: A Retrospective Cohort Study.Pulmonary medicine · 2026Article
- Advances in Plant-Derived Extracellular Vesicle Extraction Methods and Pharmacological Effects.Biology · 2025Review
- Broad-Spectrum Adverse Events of Special Interests Based on Immune Response Following COVID-19 Vaccination: A Large-Scale Population-Based Cohort Study.Journal of clinical medicine · 2025Article
- Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in East Asia and the Pacific Region: Longitudinal Trend Analysis.JMIR public health and surveillance · 2025Article
- Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.Current medicinal chemistry · 2025Article
- Identification of blood immunological biomarkers of SARS-CoV-2 infection during pandemic in Poland.Frontiers in immunology · 2025Article
- Symptom Severity and Duration of COVID-19 Are Correlated with the Healthy Eating Index (HEI) Among Hospitalized Elderly Patients.Medical journal of the Islamic Republic of Iran · 2025Article
- Identification of potential hub genes and drugs in septic kidney injury: a bioinformatic analysis with preliminary experimental validation.Frontiers in medicine · 2025Article
- Structure and Function of the SARS-CoV-2 6-HB Fusion Core and Peptide-based Fusion Inhibitors: A Review.Current medicinal chemistry · 2025Review
- Antioxidant Nutraceuticals: Their Adjunct Role in the Management of COVID-19 Infections and Post-COVID Syndrome.Infectious disorders drug targets · 2025Review
- Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Canada: Longitudinal Trend Analysis.JMIR public health and surveillance · 2024Article
- Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Sub-Saharan Africa: Longitudinal Trend Analysis.JMIR public health and surveillance · 2024Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic β-coronaviruses which infects human. Early diagnosis of COVID-19 is the most critical step to treat infection. The diagnostic tools are generally molecular methods, serology and viral culture. Recently CRISPR-based method has been investigated to diagnose and treat coronavirus infection. The emergence of 2019-nCoV during the influenza season, has led to the extensive use of antibiotics and neuraminidase enzyme inhibitors, taken orally and intravenously. Currently, antiviral inhibitors of SARS and MERS spike proteins, neuraminidase inhibitors, anti-inflammatory drugs and EK1 peptide are the available therapeutic options for SARS-CoV-2 infected individuals. In addition, Chloroquine, which was previously used for malarial and autoimmune disease, has shown efficacy in the 2019-nCoV infection treatment. In severe hypoxaemia, a combination of antibiotics, α-interferon, lopinavir and mechanical ventilation can effectively mitigate the symptoms. Comprehensive knowledge on the innate and adaptive immune responses, will make it possible to propose potent antiviral drugs with their effective therapeutic measures for the prevention of viral infection. This therapeutic strategy will help patients worldwide to protect themselves against severe and fatal viral infections, that potentially can evolve and develop drug resistance, and to reduce mortality rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.